Biohaven Pharmaceutical Holding Co. received approval from the U.S. FDA for NURTEC ODT (rimegepant) for the acute treatment of migraine in adults. NURTEC ODT has been developed in partnership with Catalent using its Zydis orally disintegrating tablet (ODT) technology to create a freeze-dried tablet that disperses almost instantly in the mouth without water. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting ODT.
